APA (7th ed.) Citation

Jones, L., Rittberg, R., Leung, B., Shokoohi, A., Pender, A., Wong, S., . . . Ho, C. (2022, November). Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing. Current Oncology.

Chicago Style (17th ed.) Citation

Jones, Lauren, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, and Cheryl Ho. "Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing." Current Oncology Nov. 2022.

MLA (9th ed.) Citation

Jones, Lauren, et al. "Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing." Current Oncology, Nov. 2022.